Special Issue "Nanomaterials for Cancer Diagnosis and Therapy"
Deadline for manuscript submissions: closed (31 May 2020).
Interests: nanomedicine; stimuli-responsive drug nanocarriers; nano-oncology; nanomotors for clinical diagnosis; nanomaterials; development of targeting moieties based on synthetic small molecules for antitumoral therapy; protein encapsulation; polymeric nanocapsules for protein delivery in medicine; nanorobots
Special Issues and Collections in MDPI journals
2. Departament de Química, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Barcelona, Spain
Interests: nanomedicine; nanoparticles; nanomaterials; drug delivery; bioimaging; nanostructured coordination polymers for biomedical applications; synthesis and characterization of hybrid nanoparticles; polymeric nanoparticles, novel strategies for cancer therapy; theranostics
Interests: nanomedicine; liposomes; gene transfection; microfluidics; drug delivery; stimuli-responsive nanodevices
Special Issues and Collections in MDPI journals
Nanotechnology has become a powerful weapon in the fight against cancer. The development of precisely engineered nanoparticles able to overcome biological barriers, specifically recognize and destroy a single type of cancer cell, and accumulate preferentially in tumours, offers a new and potent arsenal to oncologists. Inorganic and organic (or polymeric) nanoparticles have been widely explored for therapeutic and diagnostic applications in cancer treatment. Normally, single nanoparticles are often used and functionalized with organic or polymeric ligands to improve their stability, biocompatibility, and functionality. While individual nanoparticles are no doubt exciting, ensemble of interacting nanoparticles can exhibit a rich variety of novel and extremely useful collective properties that can be radically different from their individual characteristics. These new synergistic properties are originated from coupling interactions in the ensemble of nanoparticles. It is, therefore, expected that the ability to design hybrid structures with tailored spatial arrangements of nanoparticles may facilitate the utilization of nanoparticles in biomedical applications. Recent advances in nanomedicine raise exciting possibilities for future nanoparticle applications in personalized cancer therapy, and new strategies for building hybrid nanostructures are offering interesting platforms, such as effective multimodality cancer imaging (i.e., photothermal, photoacoustic, and magnetic resonance imaging) and combinational cancer therapy (i.e., photothermal ablation of tumors, photodynamic therapy, and targeted delivery-based chemotherapy).
In this Special Issue, we invite investigators to contribute original research articles as well as review articles that are related to the application of hybrid nanoparticles as multifunctional platforms in the treatment and early diagnosis of cancer. We are particularly interested in research directed toward improving the effectivity and selectivity properties of different nanoparticles for treatment or bioimaging purposes. Potential topics include, but are not limited to:
- Theranostic nanoparticles for cancer treatment
- Nanoparticles as contrast agents for bioimaging
- Nanoparticles as biosensors
- Novel therapies based on nanomaterials for cancer treatment and diagnosis
- Clinical studies and therapeutic and diagnostic efficacy of anti-cancer nanoparticles
- Biocompatibility and toxicity studies of nanoparticles for cancer treatment.
Dr. Alejandro Baeza
Dr. Fernando Novio
Dr. Juan Luis Paris
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- hybrid nanoparticles
- cancer therapy
- drug delivery
- clinical trials
- targeting moieties